Posted on January 7, 2017 by Sitemaster
An article published on line last year in Anticancer Research has just come to our attention. It puts forward the relatively simple proposal that by combining androgen deprivation therapy (ADT) with estrogen deprivation therapy (EDT) we might be able to significantly impact the risk for development of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen, combination, deprivation, estrogen | 17 Comments »
Posted on June 3, 2014 by Sitemaster
The Prostate Adenocarcinoma: TransCutaneous Hormones or PATCH trial is an ongoing study in the UK that was designed (in a series of stages) to determine whether estrogen patch therapy might be at least no worse than (i.e., “non-inferior” to) LHRH agonist therapy in suppressing androgens to castrate level. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, estrogen, PATCH, suppression, transdermal | 2 Comments »
Posted on October 25, 2010 by Sitemaster
Today’s news reports address:
- Urinary estrogen metabolites and prostate cancer risk
- Prostate hyperthermia in combination with radiation and hormone therapy
- Stem cells and development of androgen resistance
- Reviews of the appropriate management of high-risk, localized prostate cancer and the use of androgen deprivation therapy (ADT) … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, estrogen, hyperthermia, metabolite, stem cells | Leave a comment »
Posted on June 22, 2010 by Sitemaster
From 1973 to 1993 the estrogenic insecticide chlordecone (marketed as Kepone) was widely used in the French West Indies to control pests in the banana crop. In the USA it was once used to bait household insect traps. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: chlordecone, estrogen, insecticide, risk | Leave a comment »
Posted on November 5, 2009 by Sitemaster
Other news reports today — from sources not related to the ASTRO annual meeting — address such topics as:
- Perceptions about the US Preventive Services Task Force recommendations regarding the use of PSA testing men men > 75 years
- Renal insufficiency in men of long-term drug therapy for prostate cancer
- Cetuximab + doxirubicin in the treatment of CRPC
- The mechanism of action of estrogens in treatment of advanced prostate cancer … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cetruximab, doxirubicin, estrogen, PSA testing, renal in sufficiency, USPSTF | Leave a comment »
Posted on August 21, 2009 by Sitemaster
In today’s reports we note items related to:
- Whether add-back estrogen improves cognitive function in men on ADT
- Exercise and its impact on the side effects of ADT
- A new technique for delivering prostate cancer “vaccines”
- The potential of VEGF inhibitors in prostate cancer treatment … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapoy, cognitive function, electroporation, estrogen, exercise, vaccine, VEGF inhibitor | Leave a comment »
Posted on May 14, 2009 by Sitemaster
News reports today cover such issues as:
- Vitamin D and its possible role in development of prostate cancer
- Genetic testing among hereditary prostate cancer families
- Sex hormone levels and cognitive function in older men … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: cognitive function, epidemiology, estrogen, etiology, genetic testing, heredity, testosterobe, vitamin D | Leave a comment »
